 Brian Stauffer
Concepts (453)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 12 | 2023 | 1059 | 2.810 |
Why?
| | Endothelium, Vascular | 34 | 2023 | 848 | 2.660 |
Why?
| | Cardiomyopathy, Dilated | 12 | 2021 | 346 | 1.920 |
Why?
| | Endothelin-1 | 14 | 2023 | 167 | 1.900 |
Why?
| | Vasodilation | 23 | 2023 | 416 | 1.770 |
Why?
| | Heart Ventricles | 11 | 2021 | 711 | 1.490 |
Why?
| | Metoprolol | 2 | 2022 | 37 | 1.380 |
Why?
| | Vasoconstriction | 12 | 2023 | 186 | 1.310 |
Why?
| | Myocytes, Cardiac | 9 | 2023 | 448 | 1.290 |
Why?
| | Fibrinolysis | 9 | 2023 | 158 | 1.260 |
Why?
| | Myocardium | 11 | 2017 | 911 | 1.160 |
Why?
| | Blood Pressure | 12 | 2022 | 1537 | 1.090 |
Why?
| | Obesity | 19 | 2023 | 2514 | 1.090 |
Why?
| | Receptors, Adrenergic, beta | 3 | 2016 | 125 | 1.050 |
Why?
| | Heart Failure | 10 | 2023 | 1952 | 0.970 |
Why?
| | MicroRNAs | 10 | 2021 | 601 | 0.940 |
Why?
| | Nebivolol | 3 | 2022 | 9 | 0.930 |
Why?
| | Exercise | 12 | 2023 | 1641 | 0.900 |
Why?
| | Vasodilator Agents | 18 | 2023 | 305 | 0.860 |
Why?
| | Overweight | 9 | 2019 | 472 | 0.850 |
Why?
| | Postmenopause | 8 | 2023 | 303 | 0.840 |
Why?
| | Qigong | 1 | 2022 | 1 | 0.810 |
Why?
| | Isoproterenol | 4 | 2018 | 107 | 0.780 |
Why?
| | Forearm | 15 | 2021 | 112 | 0.770 |
Why?
| | C-Reactive Protein | 6 | 2015 | 362 | 0.750 |
Why?
| | Resistance Training | 1 | 2023 | 113 | 0.750 |
Why?
| | Male | 85 | 2023 | 55655 | 0.720 |
Why?
| | Aging | 13 | 2022 | 1621 | 0.720 |
Why?
| | Nitric Oxide | 8 | 2023 | 827 | 0.700 |
Why?
| | Middle Aged | 68 | 2023 | 26801 | 0.690 |
Why?
| | Sleep Deprivation | 5 | 2021 | 166 | 0.670 |
Why?
| | Mendelian Randomization Analysis | 1 | 2019 | 43 | 0.660 |
Why?
| | Cell-Derived Microparticles | 4 | 2023 | 58 | 0.650 |
Why?
| | Troponin I | 1 | 2019 | 68 | 0.650 |
Why?
| | Tissue Plasminogen Activator | 10 | 2023 | 225 | 0.650 |
Why?
| | Mitochondria, Heart | 3 | 2020 | 73 | 0.640 |
Why?
| | Heart Diseases | 3 | 2013 | 330 | 0.630 |
Why?
| | Meta-Analysis as Topic | 1 | 2019 | 161 | 0.630 |
Why?
| | Coronary Disease | 2 | 2019 | 347 | 0.620 |
Why?
| | Cardiolipins | 2 | 2020 | 72 | 0.620 |
Why?
| | Humans | 101 | 2023 | 114925 | 0.610 |
Why?
| | Antihypertensive Agents | 5 | 2017 | 429 | 0.610 |
Why?
| | Female | 73 | 2023 | 59571 | 0.600 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 2 | 2017 | 9 | 0.590 |
Why?
| | Calcium | 4 | 2021 | 1104 | 0.590 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 468 | 0.590 |
Why?
| | Regional Blood Flow | 18 | 2023 | 424 | 0.580 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 160 | 0.570 |
Why?
| | Rest | 3 | 2022 | 103 | 0.570 |
Why?
| | Vasoconstrictor Agents | 6 | 2023 | 112 | 0.560 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2016 | 11 | 0.560 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2023 | 1215 | 0.550 |
Why?
| | Shock, Cardiogenic | 1 | 2017 | 53 | 0.550 |
Why?
| | Heart Arrest | 1 | 2020 | 289 | 0.540 |
Why?
| | Sex Characteristics | 6 | 2017 | 635 | 0.540 |
Why?
| | Epoprostenol | 1 | 2017 | 133 | 0.530 |
Why?
| | Arrhythmias, Cardiac | 1 | 2018 | 279 | 0.530 |
Why?
| | Heart Rate | 2 | 2022 | 705 | 0.520 |
Why?
| | Endothelial Cells | 7 | 2020 | 685 | 0.510 |
Why?
| | Cardiovascular Diseases | 9 | 2022 | 1729 | 0.500 |
Why?
| | Myocardial Infarction | 2 | 2017 | 929 | 0.500 |
Why?
| | YY1 Transcription Factor | 1 | 2015 | 27 | 0.500 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.490 |
Why?
| | Coronavirus Infections | 1 | 2020 | 334 | 0.490 |
Why?
| | Ventricular Dysfunction, Right | 2 | 2017 | 218 | 0.490 |
Why?
| | Phosphorylation | 6 | 2021 | 1572 | 0.480 |
Why?
| | Cardiomegaly | 1 | 2015 | 159 | 0.460 |
Why?
| | Circulating MicroRNA | 3 | 2019 | 24 | 0.450 |
Why?
| | Adult | 40 | 2023 | 30604 | 0.450 |
Why?
| | Muscle Tonus | 2 | 2010 | 18 | 0.430 |
Why?
| | Acetylcholine | 14 | 2023 | 178 | 0.430 |
Why?
| | Muscle, Smooth, Vascular | 4 | 2010 | 417 | 0.430 |
Why?
| | Transcriptome | 2 | 2021 | 728 | 0.420 |
Why?
| | Connexin 43 | 2 | 2012 | 23 | 0.410 |
Why?
| | Sleep | 5 | 2021 | 632 | 0.410 |
Why?
| | Gene Expression Regulation | 5 | 2016 | 2324 | 0.400 |
Why?
| | Pandemics | 1 | 2020 | 1325 | 0.400 |
Why?
| | Peptides, Cyclic | 7 | 2013 | 254 | 0.400 |
Why?
| | Aged | 33 | 2023 | 19120 | 0.390 |
Why?
| | Heart-Assist Devices | 2 | 2016 | 485 | 0.390 |
Why?
| | Heart | 6 | 2021 | 609 | 0.380 |
Why?
| | Atherosclerosis | 2 | 2019 | 342 | 0.370 |
Why?
| | Plaque, Atherosclerotic | 1 | 2011 | 44 | 0.370 |
Why?
| | Stroke | 1 | 2019 | 1019 | 0.370 |
Why?
| | Age Factors | 10 | 2018 | 2891 | 0.350 |
Why?
| | Body Composition | 7 | 2023 | 585 | 0.350 |
Why?
| | Health | 1 | 2010 | 74 | 0.340 |
Why?
| | Ventricular Remodeling | 3 | 2021 | 227 | 0.340 |
Why?
| | Bone Diseases, Metabolic | 1 | 2010 | 53 | 0.340 |
Why?
| | Disease | 1 | 2010 | 85 | 0.330 |
Why?
| | Child, Preschool | 13 | 2021 | 9083 | 0.330 |
Why?
| | beta 2-Microglobulin | 1 | 2008 | 45 | 0.320 |
Why?
| | Testosterone | 2 | 2022 | 343 | 0.320 |
Why?
| | Physical Endurance | 3 | 2013 | 231 | 0.310 |
Why?
| | Heart Defects, Congenital | 3 | 2021 | 665 | 0.310 |
Why?
| | Metabolic Syndrome | 4 | 2016 | 323 | 0.310 |
Why?
| | Prehypertension | 3 | 2014 | 24 | 0.310 |
Why?
| | Child | 19 | 2021 | 18362 | 0.310 |
Why?
| | Gender Identity | 2 | 2006 | 101 | 0.300 |
Why?
| | Nitroprusside | 12 | 2016 | 64 | 0.300 |
Why?
| | Soybean Proteins | 2 | 2014 | 10 | 0.290 |
Why?
| | RNA, Messenger | 7 | 2021 | 2558 | 0.290 |
Why?
| | Estrogen Replacement Therapy | 3 | 2013 | 116 | 0.280 |
Why?
| | Biomarkers | 10 | 2023 | 3418 | 0.270 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 523 | 0.260 |
Why?
| | Reference Values | 4 | 2016 | 741 | 0.260 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2096 | 0.260 |
Why?
| | Phosphoric Diester Hydrolases | 2 | 2016 | 44 | 0.250 |
Why?
| | Hypoplastic Left Heart Syndrome | 3 | 2017 | 110 | 0.250 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2016 | 82 | 0.230 |
Why?
| | Disease Models, Animal | 4 | 2018 | 3549 | 0.230 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2017 | 1856 | 0.230 |
Why?
| | Genomics | 1 | 2008 | 641 | 0.230 |
Why?
| | Cells, Cultured | 5 | 2019 | 3897 | 0.220 |
Why?
| | Analysis of Variance | 6 | 2016 | 1227 | 0.220 |
Why?
| | Adaptation, Physiological | 3 | 2014 | 483 | 0.220 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 81 | 0.220 |
Why?
| | Proteomics | 1 | 2008 | 844 | 0.210 |
Why?
| | Endothelin Receptor Antagonists | 4 | 2011 | 58 | 0.210 |
Why?
| | Infusions, Intra-Arterial | 5 | 2013 | 46 | 0.210 |
Why?
| | Dietary Fats | 2 | 2015 | 287 | 0.210 |
Why?
| | Cell Movement | 4 | 2014 | 867 | 0.200 |
Why?
| | Body Weight | 3 | 2023 | 868 | 0.200 |
Why?
| | Apoptosis | 6 | 2023 | 2371 | 0.200 |
Why?
| | Physical Fitness | 1 | 2003 | 179 | 0.200 |
Why?
| | Systole | 2 | 2021 | 171 | 0.200 |
Why?
| | Baroreflex | 1 | 2022 | 54 | 0.200 |
Why?
| | Hemodynamics | 2 | 2021 | 1014 | 0.200 |
Why?
| | Calcium-Binding Proteins | 2 | 2021 | 207 | 0.190 |
Why?
| | Plethysmography | 6 | 2022 | 104 | 0.190 |
Why?
| | Animals | 15 | 2021 | 31837 | 0.190 |
Why?
| | Focal Adhesions | 1 | 2021 | 42 | 0.190 |
Why?
| | Myocardial Contraction | 3 | 2019 | 312 | 0.190 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2021 | 54 | 0.190 |
Why?
| | Case-Control Studies | 10 | 2018 | 3008 | 0.190 |
Why?
| | Milrinone | 1 | 2021 | 24 | 0.180 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2011 | 57 | 0.180 |
Why?
| | Vasomotor System | 1 | 2021 | 39 | 0.180 |
Why?
| | Vascular Diseases | 1 | 2023 | 230 | 0.180 |
Why?
| | Spinal Cord Injuries | 1 | 2023 | 173 | 0.180 |
Why?
| | Estrogens | 3 | 2012 | 312 | 0.180 |
Why?
| | Serum | 2 | 2018 | 57 | 0.180 |
Why?
| | Cross-Sectional Studies | 12 | 2023 | 4406 | 0.180 |
Why?
| | Hyperemia | 1 | 2020 | 45 | 0.180 |
Why?
| | Time Factors | 7 | 2021 | 6125 | 0.180 |
Why?
| | Heart Transplantation | 3 | 2015 | 667 | 0.170 |
Why?
| | Stem Cells | 3 | 2010 | 546 | 0.170 |
Why?
| | Point-of-Care Systems | 1 | 2021 | 139 | 0.170 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2022 | 288 | 0.170 |
Why?
| | Inflammation Mediators | 2 | 2018 | 476 | 0.170 |
Why?
| | Endothelin A Receptor Antagonists | 4 | 2014 | 24 | 0.170 |
Why?
| | Telomere | 3 | 2010 | 202 | 0.160 |
Why?
| | Physical Exertion | 2 | 2014 | 211 | 0.160 |
Why?
| | Adenylyl Cyclases | 2 | 2016 | 82 | 0.160 |
Why?
| | Adolescent | 8 | 2022 | 17826 | 0.160 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 384 | 0.160 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.160 |
Why?
| | Flecainide | 1 | 2018 | 7 | 0.160 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 94 | 0.160 |
Why?
| | Endothelium | 3 | 2020 | 112 | 0.150 |
Why?
| | Guinea Pigs | 1 | 2018 | 143 | 0.150 |
Why?
| | Walking | 1 | 2022 | 424 | 0.150 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2018 | 59 | 0.150 |
Why?
| | Up-Regulation | 3 | 2018 | 812 | 0.150 |
Why?
| | Extracellular Matrix | 1 | 2021 | 436 | 0.150 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2018 | 106 | 0.150 |
Why?
| | Body Mass Index | 7 | 2017 | 1961 | 0.150 |
Why?
| | HIV | 1 | 2019 | 208 | 0.150 |
Why?
| | Cardiomyopathy, Hypertrophic | 2 | 2011 | 122 | 0.150 |
Why?
| | Down-Regulation | 2 | 2017 | 596 | 0.140 |
Why?
| | Fibrosis | 5 | 2023 | 454 | 0.140 |
Why?
| | Double-Blind Method | 3 | 2017 | 1663 | 0.140 |
Why?
| | Behavior Therapy | 1 | 2019 | 226 | 0.140 |
Why?
| | Prognosis | 6 | 2018 | 3344 | 0.140 |
Why?
| | Infant | 6 | 2017 | 7936 | 0.140 |
Why?
| | Blood Flow Velocity | 4 | 2022 | 387 | 0.140 |
Why?
| | Kearns-Sayre Syndrome | 1 | 2016 | 1 | 0.140 |
Why?
| | Bundle-Branch Block | 1 | 2017 | 29 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.140 |
Why?
| | Mitochondrial Myopathies | 1 | 2016 | 4 | 0.140 |
Why?
| | Coronary Occlusion | 1 | 2017 | 18 | 0.140 |
Why?
| | Atrial Natriuretic Factor | 1 | 2016 | 57 | 0.140 |
Why?
| | Blotting, Western | 2 | 2016 | 1151 | 0.140 |
Why?
| | Receptor, Endothelin A | 2 | 2014 | 59 | 0.140 |
Why?
| | Caspase 3 | 4 | 2011 | 238 | 0.140 |
Why?
| | Sampling Studies | 1 | 2016 | 93 | 0.140 |
Why?
| | Treatment Outcome | 3 | 2020 | 9105 | 0.140 |
Why?
| | Specimen Handling | 1 | 2018 | 156 | 0.140 |
Why?
| | Oxidation-Reduction | 2 | 2018 | 927 | 0.140 |
Why?
| | Weight Loss | 2 | 2019 | 642 | 0.140 |
Why?
| | Oxidative Stress | 4 | 2022 | 1084 | 0.140 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 535 | 0.140 |
Why?
| | Ventricular Function, Right | 1 | 2018 | 252 | 0.140 |
Why?
| | Bradykinin | 6 | 2008 | 43 | 0.130 |
Why?
| | Nitric Oxide Synthase Type III | 3 | 2023 | 184 | 0.130 |
Why?
| | Plasma | 1 | 2018 | 210 | 0.130 |
Why?
| | Exosomes | 1 | 2017 | 91 | 0.130 |
Why?
| | Diet | 2 | 2014 | 1077 | 0.130 |
Why?
| | Mice | 8 | 2015 | 14935 | 0.130 |
Why?
| | Nitric Oxide Synthase | 4 | 2017 | 209 | 0.130 |
Why?
| | Rats | 4 | 2021 | 4963 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2019 | 696 | 0.130 |
Why?
| | Collagen Type III | 1 | 2015 | 18 | 0.130 |
Why?
| | Action Potentials | 1 | 2018 | 406 | 0.130 |
Why?
| | Blood Pressure Determination | 2 | 2016 | 122 | 0.120 |
Why?
| | Administration, Inhalation | 1 | 2017 | 642 | 0.120 |
Why?
| | omega-N-Methylarginine | 3 | 2015 | 25 | 0.120 |
Why?
| | Phosphodiesterase 3 Inhibitors | 1 | 2014 | 13 | 0.120 |
Why?
| | Ascorbic Acid | 2 | 2021 | 110 | 0.120 |
Why?
| | Lipids | 3 | 2009 | 582 | 0.120 |
Why?
| | Cytoskeletal Proteins | 1 | 2015 | 145 | 0.120 |
Why?
| | Tissue Donors | 1 | 2016 | 317 | 0.120 |
Why?
| | Linear Models | 1 | 2016 | 770 | 0.120 |
Why?
| | Microfilament Proteins | 1 | 2015 | 127 | 0.120 |
Why?
| | Gene Expression | 3 | 2017 | 1422 | 0.120 |
Why?
| | Young Adult | 10 | 2023 | 10476 | 0.110 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1700 | 0.110 |
Why?
| | Receptor, Endothelin B | 2 | 2014 | 51 | 0.110 |
Why?
| | Myosin Heavy Chains | 4 | 2014 | 177 | 0.110 |
Why?
| | Endothelial Progenitor Cells | 1 | 2014 | 18 | 0.110 |
Why?
| | Diet, High-Fat | 1 | 2015 | 225 | 0.110 |
Why?
| | Adiposity | 3 | 2016 | 457 | 0.110 |
Why?
| | Blood Glucose | 4 | 2013 | 1821 | 0.110 |
Why?
| | Interleukin-6 | 4 | 2022 | 676 | 0.110 |
Why?
| | Anti-HIV Agents | 1 | 2019 | 668 | 0.100 |
Why?
| | Animals, Newborn | 3 | 2021 | 777 | 0.100 |
Why?
| | Phytoestrogens | 1 | 2012 | 13 | 0.100 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 39 | 0.100 |
Why?
| | Blood Vessels | 1 | 2014 | 180 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 219 | 0.100 |
Why?
| | Piperidines | 2 | 2013 | 162 | 0.100 |
Why?
| | Cytokines | 2 | 2010 | 1843 | 0.100 |
Why?
| | Oligopeptides | 2 | 2013 | 235 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4427 | 0.100 |
Why?
| | Hysterectomy | 1 | 2012 | 106 | 0.100 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2017 | 444 | 0.100 |
Why?
| | Glucose Intolerance | 1 | 2013 | 138 | 0.100 |
Why?
| | Signal Transduction | 6 | 2016 | 4524 | 0.100 |
Why?
| | Mice, Transgenic | 2 | 2015 | 1953 | 0.100 |
Why?
| | Plasminogen Activator Inhibitor 1 | 3 | 2023 | 83 | 0.100 |
Why?
| | Fatty Acids | 1 | 2014 | 382 | 0.100 |
Why?
| | Risk Factors | 9 | 2018 | 8637 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2017 | 316 | 0.090 |
Why?
| | Abdominal Fat | 1 | 2011 | 39 | 0.090 |
Why?
| | Recovery of Function | 1 | 2015 | 572 | 0.090 |
Why?
| | Risk Assessment | 2 | 2016 | 2975 | 0.090 |
Why?
| | Organ Specificity | 1 | 2011 | 270 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 744 | 0.090 |
Why?
| | Estradiol | 1 | 2013 | 455 | 0.090 |
Why?
| | RNA | 1 | 2016 | 810 | 0.090 |
Why?
| | Dyslipidemias | 1 | 2012 | 154 | 0.090 |
Why?
| | Cholesterol, LDL | 1 | 2012 | 307 | 0.090 |
Why?
| | Chemotaxis | 1 | 2010 | 130 | 0.090 |
Why?
| | Rats, Sprague-Dawley | 3 | 2021 | 2211 | 0.080 |
Why?
| | Sleep Wake Disorders | 1 | 2013 | 232 | 0.080 |
Why?
| | NF-kappa B | 2 | 2023 | 637 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2015 | 572 | 0.080 |
Why?
| | Enzyme Inhibitors | 4 | 2017 | 752 | 0.080 |
Why?
| | Norepinephrine | 1 | 2009 | 207 | 0.080 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 101 | 0.080 |
Why?
| | Endothelin-Converting Enzymes | 1 | 2008 | 10 | 0.080 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2008 | 21 | 0.080 |
Why?
| | Metalloendopeptidases | 1 | 2008 | 55 | 0.080 |
Why?
| | Muscarinic Agonists | 1 | 2008 | 9 | 0.080 |
Why?
| | United States | 3 | 2020 | 12209 | 0.080 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2021 | 36 | 0.080 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 345 | 0.080 |
Why?
| | Calcium Channel Blockers | 1 | 2008 | 115 | 0.070 |
Why?
| | Vascular Stiffness | 1 | 2012 | 408 | 0.070 |
Why?
| | Infant, Newborn | 2 | 2017 | 5035 | 0.070 |
Why?
| | Substance P | 2 | 2008 | 44 | 0.070 |
Why?
| | Physical Conditioning, Animal | 2 | 2006 | 195 | 0.070 |
Why?
| | Adult Stem Cells | 1 | 2006 | 32 | 0.070 |
Why?
| | Bone Density | 1 | 2010 | 430 | 0.070 |
Why?
| | Hypertrophy | 2 | 2023 | 111 | 0.070 |
Why?
| | Retrospective Studies | 2 | 2022 | 12543 | 0.070 |
Why?
| | Brachial Artery | 2 | 2020 | 176 | 0.070 |
Why?
| | Flow Cytometry | 3 | 2019 | 1087 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2021 | 1523 | 0.070 |
Why?
| | DNA Methylation | 1 | 2010 | 496 | 0.070 |
Why?
| | Dinucleotide Repeats | 1 | 2005 | 4 | 0.060 |
Why?
| | Colony-Forming Units Assay | 3 | 2014 | 89 | 0.060 |
Why?
| | Myocardial Ischemia | 1 | 2006 | 234 | 0.060 |
Why?
| | Organ Size | 1 | 2006 | 435 | 0.060 |
Why?
| | HIV Infections | 1 | 2019 | 2469 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2014 | 499 | 0.060 |
Why?
| | Triglycerides | 2 | 2005 | 470 | 0.060 |
Why?
| | Estrogen Receptor alpha | 1 | 2005 | 121 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 372 | 0.060 |
Why?
| | Diacetyl | 1 | 2003 | 7 | 0.060 |
Why?
| | Endothelin B Receptor Antagonists | 2 | 2014 | 11 | 0.060 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2003 | 16 | 0.060 |
Why?
| | Quadriplegia | 1 | 2023 | 12 | 0.060 |
Why?
| | von Willebrand Factor | 1 | 2023 | 56 | 0.060 |
Why?
| | Induced Pluripotent Stem Cells | 2 | 2017 | 182 | 0.050 |
Why?
| | Sex Factors | 3 | 2014 | 1721 | 0.050 |
Why?
| | Actinin | 1 | 2023 | 13 | 0.050 |
Why?
| | Thrombophilia | 1 | 2023 | 66 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2023 | 89 | 0.050 |
Why?
| | Inflammation | 2 | 2019 | 2485 | 0.050 |
Why?
| | Hypertriglyceridemia | 1 | 2003 | 34 | 0.050 |
Why?
| | Fenofibrate | 1 | 2003 | 24 | 0.050 |
Why?
| | Troponin T | 1 | 2023 | 49 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2010 | 1749 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 2008 | 1317 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 213 | 0.050 |
Why?
| | Cyclic AMP | 2 | 2014 | 225 | 0.050 |
Why?
| | Endopeptidase K | 1 | 2021 | 14 | 0.050 |
Why?
| | Ribonucleases | 1 | 2021 | 52 | 0.050 |
Why?
| | Vital Capacity | 1 | 2002 | 257 | 0.050 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 126 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2022 | 104 | 0.050 |
Why?
| | Serum Response Factor | 1 | 2021 | 28 | 0.050 |
Why?
| | Oxygen Consumption | 3 | 2012 | 588 | 0.050 |
Why?
| | Microscopy, Atomic Force | 1 | 2021 | 113 | 0.050 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 49 | 0.050 |
Why?
| | Lymphocyte Count | 2 | 2011 | 133 | 0.050 |
Why?
| | Healthy Lifestyle | 1 | 2021 | 28 | 0.050 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 64 | 0.050 |
Why?
| | Endothelins | 1 | 2021 | 61 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2016 | 718 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2023 | 449 | 0.040 |
Why?
| | Mice, Inbred C57BL | 4 | 2014 | 4718 | 0.040 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 119 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2012 | 6363 | 0.040 |
Why?
| | Cytochromes c | 2 | 2010 | 63 | 0.040 |
Why?
| | Chemokine CXCL12 | 2 | 2010 | 74 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2199 | 0.040 |
Why?
| | Cardiorespiratory Fitness | 1 | 2019 | 35 | 0.040 |
Why?
| | Risk Reduction Behavior | 1 | 2021 | 200 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 591 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 386 | 0.040 |
Why?
| | Disease Progression | 1 | 2006 | 2392 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 390 | 0.040 |
Why?
| | HIV Antibodies | 1 | 2019 | 49 | 0.040 |
Why?
| | Telomerase | 2 | 2011 | 206 | 0.040 |
Why?
| | Infusions, Intravenous | 2 | 2011 | 372 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 182 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 546 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 530 | 0.040 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 36 | 0.040 |
Why?
| | Electrocardiography | 1 | 2021 | 562 | 0.040 |
Why?
| | Outpatients | 1 | 2021 | 328 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2019 | 147 | 0.040 |
Why?
| | Freezing | 1 | 2018 | 85 | 0.040 |
Why?
| | Fasting | 2 | 2013 | 242 | 0.040 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 16 | 0.030 |
Why?
| | Cell Size | 1 | 2017 | 81 | 0.030 |
Why?
| | Galectin 3 | 1 | 2016 | 18 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 57 | 0.030 |
Why?
| | Electron Transport | 1 | 2016 | 108 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1126 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 322 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2106 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2017 | 71 | 0.030 |
Why?
| | Infusions, Intraosseous | 1 | 2016 | 20 | 0.030 |
Why?
| | Hot Temperature | 1 | 2018 | 304 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2017 | 149 | 0.030 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 171 | 0.030 |
Why?
| | Drug Discovery | 1 | 2016 | 124 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 294 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2640 | 0.030 |
Why?
| | Mutation | 1 | 2006 | 3353 | 0.030 |
Why?
| | Myogenic Regulatory Factors | 2 | 2006 | 49 | 0.030 |
Why?
| | MEF2 Transcription Factors | 2 | 2006 | 55 | 0.030 |
Why?
| | Cardiomegaly, Exercise-Induced | 1 | 2014 | 3 | 0.030 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2014 | 33 | 0.030 |
Why?
| | Caseins | 1 | 2014 | 20 | 0.030 |
Why?
| | Colorado | 2 | 2016 | 4089 | 0.030 |
Why?
| | Interleukin-18 | 2 | 2006 | 219 | 0.030 |
Why?
| | Consensus | 1 | 2016 | 534 | 0.030 |
Why?
| | Algorithms | 1 | 2021 | 1474 | 0.030 |
Why?
| | Cross-Over Studies | 2 | 2008 | 441 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 93 | 0.030 |
Why?
| | Heart Conduction System | 1 | 2014 | 82 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 153 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 448 | 0.030 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 175 | 0.030 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 117 | 0.030 |
Why?
| | Models, Cardiovascular | 1 | 2014 | 178 | 0.030 |
Why?
| | Age of Onset | 1 | 2014 | 448 | 0.030 |
Why?
| | Genistein | 1 | 2012 | 11 | 0.030 |
Why?
| | Interleukin-1 | 1 | 2016 | 966 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 797 | 0.030 |
Why?
| | Ovariectomy | 1 | 2012 | 116 | 0.030 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 157 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 96 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 172 | 0.020 |
Why?
| | Cholinergic Agonists | 1 | 2011 | 7 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2012 | 201 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 347 | 0.020 |
Why?
| | Administration, Oral | 1 | 2013 | 731 | 0.020 |
Why?
| | Obesity, Abdominal | 1 | 2011 | 37 | 0.020 |
Why?
| | Carotid Arteries | 1 | 2012 | 180 | 0.020 |
Why?
| | Waist Circumference | 1 | 2011 | 122 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2011 | 119 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2006 | 1134 | 0.020 |
Why?
| | Cardiomyopathies | 1 | 2014 | 300 | 0.020 |
Why?
| | Anthropometry | 1 | 2011 | 180 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2011 | 171 | 0.020 |
Why?
| | Plant Lectins | 1 | 2010 | 8 | 0.020 |
Why?
| | Phenotype | 2 | 2011 | 2817 | 0.020 |
Why?
| | Staurosporine | 1 | 2010 | 21 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2010 | 71 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 6218 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 195 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 292 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 330 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 633 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 400 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 947 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2008 | 47 | 0.020 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2008 | 38 | 0.020 |
Why?
| | Prevalence | 1 | 2014 | 2251 | 0.020 |
Why?
| | Computational Biology | 1 | 2011 | 531 | 0.020 |
Why?
| | Arm | 1 | 2007 | 104 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2007 | 134 | 0.020 |
Why?
| | Probability | 1 | 2007 | 291 | 0.020 |
Why?
| | Lipoproteins, LDL | 1 | 2006 | 128 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2006 | 61 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2006 | 78 | 0.020 |
Why?
| | Thymidine | 1 | 2005 | 58 | 0.020 |
Why?
| | NFATC Transcription Factors | 1 | 2006 | 78 | 0.020 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2006 | 127 | 0.020 |
Why?
| | Caspases | 1 | 2006 | 245 | 0.020 |
Why?
| | Glycogen | 1 | 2004 | 51 | 0.010 |
Why?
| | Thrombosis | 1 | 2007 | 297 | 0.010 |
Why?
| | Calmodulin | 1 | 2004 | 71 | 0.010 |
Why?
| | Ventricular Myosins | 1 | 2003 | 33 | 0.010 |
Why?
| | Adenine | 1 | 2005 | 219 | 0.010 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 130 | 0.010 |
Why?
| | Diastole | 1 | 2003 | 131 | 0.010 |
Why?
| | Cholesterol | 1 | 2005 | 368 | 0.010 |
Why?
| | Sarcomeres | 1 | 2003 | 90 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2003 | 410 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2003 | 262 | 0.010 |
Why?
| | Muscarinic Antagonists | 1 | 2003 | 26 | 0.010 |
Why?
| | Physical Education and Training | 1 | 2003 | 61 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2003 | 338 | 0.010 |
Why?
| | Hypolipidemic Agents | 1 | 2003 | 87 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 612 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2003 | 151 | 0.010 |
Why?
| | Lipoproteins | 1 | 2003 | 160 | 0.010 |
Why?
| | Models, Animal | 1 | 2003 | 346 | 0.010 |
Why?
| | Mutation, Missense | 1 | 2003 | 295 | 0.010 |
Why?
| | Progesterone | 1 | 2003 | 232 | 0.010 |
Why?
| | Life Style | 1 | 2003 | 430 | 0.010 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 360 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1317 | 0.010 |
Why?
| | Cohort Studies | 1 | 2007 | 4903 | 0.010 |
Why?
| | Transcription Factors | 1 | 2004 | 1530 | 0.010 |
Why?
| | Insulin | 1 | 2005 | 2079 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2003 | 1072 | 0.010 |
Why?
|
|
Stauffer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|